A novel approach to development of monoclonal antibodies using native antigen for immunization and recombinant antigen for screening

Hybridoma
Wei-Gang HuLes P Nagata

Abstract

The production of monoclonal antibodies (MAb) specific to microbes is rapidly growing. Finding an appropriate antigen to screen hybridoma clones has become increasingly important. However, the conventional method, in which the purified antigen from the microbe is routinely used for screening, cannot avoid selection of false positive hybridoma clones, since even highly purified antigen is found to be contaminated with some other proteins from the microbe. In this study, MAbs against anthrax protective antigen (PA), the central component of the three-part toxin secreted by Bacillus anthracis were developed using a pair of the roughly purified native PA as an immunogen and the recombinant PA as a screening antigen without any possibility of false selection, since the recombinant PA was produced by a gene engineering approach and impossible to be contaminated with any other proteins from B. anthracis. In total, nine stable hybridoma clones secreting anti-PA MAbs were developed. All of them had the same type of heavy and light chains, IgG1/kappa. The binding profiles for these anti-PA MAbs were investigated by ELISA. This novel approach to the development of MAbs should be applicable to the production of MAbs to other microbes, espe...Continue Reading

References

Aug 1, 1991·Vaccine·P C Turnbull
May 1, 1986·Infection and Immunity·B E IvinsS H Leppla
May 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·S H Leppla
Aug 6, 1997·JAMA : the Journal of the American Medical Association·R A Zilinskas
Sep 9, 1999·The New England Journal of Medicine·T C DixonP C Hanna
May 1, 2002·JAMA : the Journal of the American Medical Association·Thomas V InglesbyUNKNOWN Working Group on Civilian Biodefense
Jun 4, 2002·Nature Biotechnology·Jennifer A MaynardGeorge Georgiou
Sep 22, 2006·Infection and Immunity·David KobilerZeev Altboum
Mar 6, 2007·Annual Review of Biochemistry·John A T Young, R John Collier

❮ Previous
Next ❯

Citations

Mar 14, 2013·BioMed Research International·Wei-Gang HuJohn W Cherwonogrodzky
Aug 22, 2013·Plant Molecular Biology·Thomas De MeyerAnn Depicker
Jul 2, 2021·Protein Expression and Purification·Hee-Jin JeongByung-Gee Kim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.